A Nomogram for Predicting Progression-Free Survival in Primary Extramedullary Multiple Myeloma Using Routine Laboratory Variables.

IF 1.1 4区医学 Q3 HEMATOLOGY

Acta Haematologica Pub Date : 2025-08-20 DOI:10.1159/000548028

Yating Li, Jie Chen, Yunqi Cui, Na Hu, Wanting Ying, Hongming Huang, Xiaoyan Qu, Zhengxu Sun

{"title":"A Nomogram for Predicting Progression-Free Survival in Primary Extramedullary Multiple Myeloma Using Routine Laboratory Variables.","authors":"Yating Li, Jie Chen, Yunqi Cui, Na Hu, Wanting Ying, Hongming Huang, Xiaoyan Qu, Zhengxu Sun","doi":"10.1159/000548028","DOIUrl":null,"url":null,"abstract":"Introduction: Extramedullary involvement in multiple myeloma represents aggressive disease, with clinical stratification of primary extramedullary disease (EMD) remaining a challenge. In this study, we aimed to develop a credible nomogram utilizing routine laboratory variables to predict individual survival for primary EMD patients.Methods: We retrospectively analyzed a cohort of 60 primary EMD patients, from January 2006 to December 2022. Independent risk factors were identified and subsequently incorporated to generate a nomogram using the Cox proportional hazard regression model. Then, we classified patients into two risk groups based on the nomogram model risk score and compared their survival time using the Kaplan-Meier method.Results: After a median follow-up of 25.4 months, the median progression-free survival (PFS) of primary EMD patients was 29.4 months. Three independent prognostic factors, namely Ki67, endothelial activation stress index (EASIX), and monocyte count, were identified and subsequently incorporated to generate a nomogram using the Cox proportional hazard regression model. Nomogram performance was assessed using various metrics. Then, we classified patients into two risk groups based on the nomogram model risk score, and the Kaplan-Meier curve showed that the median PFS was significantly longer in the low-risk group compared to the high-risk group (37.1 months versus 2.6 months, p < 0.001).Conclusion: A predictive nomogram was developed and validated to evaluate the outcome of primary EMD patients.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-11"},"PeriodicalIF":1.1000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000548028","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Extramedullary involvement in multiple myeloma represents aggressive disease, with clinical stratification of primary extramedullary disease (EMD) remaining a challenge. In this study, we aimed to develop a credible nomogram utilizing routine laboratory variables to predict individual survival for primary EMD patients.

Methods: We retrospectively analyzed a cohort of 60 primary EMD patients, from January 2006 to December 2022. Independent risk factors were identified and subsequently incorporated to generate a nomogram using the Cox proportional hazard regression model. Then, we classified patients into two risk groups based on the nomogram model risk score and compared their survival time using the Kaplan-Meier method.

Results: After a median follow-up of 25.4 months, the median progression-free survival (PFS) of primary EMD patients was 29.4 months. Three independent prognostic factors, namely Ki67, endothelial activation stress index (EASIX), and monocyte count, were identified and subsequently incorporated to generate a nomogram using the Cox proportional hazard regression model. Nomogram performance was assessed using various metrics. Then, we classified patients into two risk groups based on the nomogram model risk score, and the Kaplan-Meier curve showed that the median PFS was significantly longer in the low-risk group compared to the high-risk group (37.1 months versus 2.6 months, p < 0.001).

Conclusion: A predictive nomogram was developed and validated to evaluate the outcome of primary EMD patients.

查看原文本刊更多论文

使用常规实验室变量预测原发性髓外多发性骨髓瘤无进展生存的nomogram。

目的：多发性骨髓瘤（MM）的髓外受累是一种侵袭性疾病，原发性髓外疾病（EMD）的临床分层仍然是一个挑战。在这项研究中，我们的目的是开发一个可信的nomogram，利用常规的实验室变量来预测原发性EMD患者的个体生存。方法：我们回顾性分析了2006年1月至2022年12月期间60例原发性EMD患者。确定独立风险因素，并随后使用Cox比例风险回归模型合并生成nomogram。然后，我们根据nomogram模型风险评分将患者分为两个风险组，并使用Kaplan-Meier法比较他们的生存时间。结果：中位随访25.4个月后，原发性EMD患者的中位无进展生存期（PFS）为29.4个月。三个独立的预后因素，即Ki67，内皮活化应激指数（EASIX）和单核细胞计数，被确定并随后纳入使用Cox比例风险回归模型生成nomogram。使用各种指标评估Nomogram表现。然后，我们根据nomogram模型风险评分将患者分为两个风险组，Kaplan-Meier曲线显示，低风险组的中位PFS明显高于高风险组（37.1个月vs 2.6个月）。结论：总之，我们开发并验证了一种预测nomogram模型来评估原发性EMD患者的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Haematologica 医学-血液学

CiteScore

4.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Acta Haematologica'' is a well-established and internationally recognized clinically-oriented journal featuring balanced, wide-ranging coverage of current hematology research. A wealth of information on such problems as anemia, leukemia, lymphoma, multiple myeloma, hereditary disorders, blood coagulation, growth factors, hematopoiesis and differentiation is contained in first-rate basic and clinical papers some of which are accompanied by editorial comments by eminent experts. These are supplemented by short state-of-the-art communications, reviews and correspondence as well as occasional special issues devoted to ‘hot topics’ in hematology. These will keep the practicing hematologist well informed of the new developments in the field.